Qube Research & Technologies (QRT)
ACHL

Qube Research & Technologies (QRT)’s Achilles Therapeutics ACHL Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-73
Closed -$59 – 4300
2024
Q2 		$59 Hold
73
– – ﹤0.01% 3490
2024
Q1 		$91 Hold
73
– – ﹤0.01% 4189
2023
Q4 		$65 Hold
73
– – ﹤0.01% 4054
2023
Q3 		$66 Buy
+73
New +$69 ﹤0.01% 3794

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ACHL Position: Q3 2024 in Review

Qube Research & Technologies (QRT) sold out of Achilles Therapeutics (ACHL) in Q3 2024, closing a stake of 73 shares — an estimated $59 sold.

Qube Research & Technologies (QRT) first reported a position in ACHL in Q3 2023 and held it in 4 quarters. The position peaked at $91 in Q1 2024. 22 funds tracked by Wall St. Rank hold ACHL as of Q3 2024.

  • Qube Research & Technologies (QRT) reported no remaining Achilles Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 73 Achilles Therapeutics shares in Q3 2024, an estimated $59.
  • Qube Research & Technologies (QRT) first reported a position in Achilles Therapeutics in Q3 2023 and held it in 4 quarters.
  • Qube Research & Technologies (QRT)'s Achilles Therapeutics position peaked at $91 in Q1 2024.
  • 22 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q3 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2024, filed 14 Nov 2024.